文献速递前列腺增生与排尿功能障碍

PINNACLE研究:评估Optilume BPH导管系统治疗良性前列腺增生继发下尿路症状的双盲随机假手术对照研究

The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
PubMed 文献 · J Urol · 2023-08-09

PINNACLE研究是一项前瞻性、随机、双盲、假手术对照临床试验,纳入148例50岁及以上、前列腺大小20至80g的症状性良性前列腺增生男性,按2:1随机接受Optilume BPH治疗(100例)或假手术(48例)。结果显示Optilume BPH组1年时国际前列腺症状评分(IPSS)降低11.5±7.8分,假手术组3个月时降低8.0±8.3分;Optilume BPH组最大尿流率从基线至1年改善+10.3 mL/s(+125%)。结论认为Optilume BPH可立即且持续改善梗阻症状和尿流率,同时保留勃起和射精功能,耐受良好,可在门诊或日间手术环境中完成。

要点

  • Optilume BPH组1年IPSS降低11.5±7.8分,假手术组3个月降低8.0±8.3分。
  • Optilume BPH组最大尿流率从基线至1年改善+10.3 mL/s(+125%)。
  • 治疗耐受良好,可在门诊或日间手术环境中完成,并保留勃起和射精功能。

核心结论

  • Optilume BPH治疗可立即且持续改善梗阻症状和尿流率,同时保留勃起和射精功能,治疗耐受良好,可在门诊或日间手术环境中完成。

研究设计与样本

  • PINNACLE研究为前瞻性、随机、双盲、假手术对照临床试验,在美国和加拿大18个中心纳入148例50岁及以上、有症状性良性前列腺增生且前列腺大小20至80g的男性,按2:1随机接受Optilume BPH治疗(100例)或假手术(48例),受试者和评估人员设盲至术后1年。

主要发现

  • Optilume BPH组治疗1年时IPSS降低11.5±7.8分,假手术组3个月时IPSS降低8.0±8.3分。
  • Optilume BPH组最大尿流率从基线至1年改善+10.3 mL/s(+125%)。

临床怎么用

  • 原文结论指出Optilume BPH治疗可在门诊或日间手术环境中完成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Optilume BPH Catheter System is a novel drug/device combination minimally invasive surgical therapy for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. The PINNACLE study is a prospective, randomized, double-blind, sham-controlled clinical trial evaluating the safety and efficacy of Optilume BPH against a sham surgical procedure. MATERIALS AND METHODS: Eligible patients were men 50 years or older with symptomatic benign prostatic hyperplasia and a prostate size between 20 and 80 g. Subjects were randomized 2:1 to receive treatment with Optilume BPH or a sham surgical procedure. Blinding was maintained for subjects in both arms and evaluating personnel through 1 year postprocedure. Follow-up assessments included the International Prostate Symptom Score, uroflowmetry, and other quality-of-life and sexual function assessments. RESULTS: A total of 148 men were randomized (100 active, 48 sham) at 18 centers in the U.S. and Canada. Subjects randomized to receive Optilume BPH saw a reduction in International Prostate Symptom Score of 11.5±7.8 points at 1 year posttreatment, as compared to a reduction of 8.0±8.3 points at 3 months in the sham arm. Flow rate was dramatically improved after treatment with Optilume BPH, with an improvement of +10.3 mL/s from baseline to 1 year (+125%). CONCLUSIONS: Treatment with Optilume BPH provides immediate and sustained improvements in obstructive symptoms and flow rate while preserving erectile and ejaculatory function. Treatment is well tolerated and can be done in an office or ambulatory setting.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kaplan SA, Moss J, Freedman S, et al. The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2023. PMID: 37555604. doi:10.1097/JU.0000000000003568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。